Elaine Davidson, MD
Family Medicine · Meridian, IDNPI 1093705022
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 91 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $935, 3.2 times the $291 reported in 2019.
Across 91 payments — averaging $20.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$282
- Novo Nordisk$251
- AstraZeneca$184
- Amgen$171
- Pfizer$116
- Exact Sciences$91
- plus $788 from 21 others
Across 126 payments — averaging $2389.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$168K
- Pfizer$126K
- Romark Laboratories, LC$7K
- Janssen Research & Development, LLC$1K
What the payments were for
- Food & beverage$1,87299%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 9 | $282 |
| Novo Nordisk | 14 | $251 |
| AstraZeneca | 6 | $184 |
| Amgen | 9 | $171 |
| Pfizer | 6 | $116 |
| Exact Sciences | 4 | $91 |
| Shield Therapeutics Inc | 4 | $85 |
| Lilly USA, LLC | 4 | $72 |
| Mylan Specialty L.p. | 2 | $67 |
| Corcept Therapeutics | 4 | $61 |
| Phathom Pharmaceuticals, Inc. | 4 | $60 |
| GSK | 3 | $60 |
| AbbVie(2 entities) | 3 | $49 |
| Astellas Pharma US Inc | 2 | $47 |
| E.r. Squibb & Sons, L.L.C. | 2 | $39 |
| Abbott | 2 | $35 |
| Johnson & Johnson | 2 | $29 |
| Vertex | 1 | $25 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Dexcom, Inc. | 1 | $22 |
| Novartis | 1 | $21 |
| Stryker | 1 | $21 |
| Recor Medical Inc | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Organon | 1 | $17 |
| Merck | 1 | $12 |
| Corium, LLC | 2 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,883 in reported general payments places this provider in the 80th percentile of 803 family medicine providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 42 | $52,421 |
| TrulicityDulaglutide | 32 | $34,010 |
| OzempicSemaglutide | 19 | $33,963 |
| JardianceEmpagliflozin | 22 | $31,922 |
| JanuviaSitagliptin Phosphate | 31 | $24,680 |
| MounjaroTirzepatide | 12 | $12,392 |
| FarxigaDapagliflozin Propanediol | 17 | $11,354 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $8,863 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $8,403 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 19 | $6,538 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 27 | $5,395 |
| Arnuity ElliptaFluticasone Furoate | 14 | $4,927 |
| Omeprazole | 262 | $4,905 |
| Duloxetine Hcl | 133 | $4,672 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 146 | $4,295 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $116 | $52,42142 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $72 | $46,40244 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $282 | $40,32535 claims |
| Novo NordiskOzempic | $251 | $33,96319 claims |
| MerckJanuvia | $12 | $24,68031 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $60 | $13,79026 claims |
| AstraZenecaFarxiga | $184 | $11,35417 claims |
| AbbVieSynthroid | $49 | $1,08720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 803 family medicine providers in Idaho.
Other family medicine in Meridian
- David ButukMeridian$206K
- Timothy McHughMeridian$165K
- Mark JohnsonMeridian$10K
- Jason LudwigMeridian$7K
- Jacob SmithMeridian$7K
- Ginger AllenMeridian$6K
- George ThomasMeridian$6K
- Mark TurnerMeridian$6K
- Aaron MoorhouseMeridian$5K
- Kenneth CongerSandpoint$266K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.